Skip to content
Breathing, swallowing or vision problems: call the emergency services (15 or 112 in France).

Botox not working: why, and what can you do?

Botulinum toxin that seems not to work has often simply not reached its peak effect yet. When the lack of effect persists, the labels list four possible causes: the choice of muscles, the technique, an insufficient dose and, more rarely, antibodies. Here is how to tell the difference and what to ask your doctor.

You have had a botulinum toxin injection and you see no change, or much less than expected. Before concluding that it has failed, check how much time has passed, then consider the causes described in the official labels. This page is part of our guide to problems after an injection, which also covers adverse effects and effects that are too strong.

Is it too early to judge?

This is the first question to ask, because botulinum toxin does not act immediately. With a type A toxin, the first effects usually appear within 2 to 3 days2,3, sometimes only within the following week1. The peak effect is seen around day 30 for several products2,3: a result judged after one week is therefore often not the final one.

With the short-acting botulinum toxin (serotype E), the timeline is different: the effects begin 8 hours after the injection, peak around day 7 and generally last 2 to 3 weeks4. If you judge the result one month after an injection of this kind, the effect has most likely already gone, which is normal. As of 9 October 2026, this toxin is approved in the European Union (since 15 July 2026) and in Canada (since 22 June 2026)6,7.

If you do not know which product was used, ask the doctor: the short-acting toxin label actually requires the name and batch number of the product given to be recorded4.

When is treatment considered to have failed?

One type A toxin label defines failure as no significant improvement one month after the first session, compared with the starting point1. Bear in mind that, even in trials, not all patients respond in the same way: thirty days after the injection, 80% of patients treated for frown lines were considered responders by the investigator1. A partial response is therefore not necessarily abnormal.

For the short-acting toxin, data in people over 65 are limited, and the response rate at day 7 was lower in this group: 58% according to the investigator, 37% according to the patients4.

What are the possible causes?

When failure is confirmed, the labels ask for its causes to be analysed; they can vary1,2:

  • the choice of injected muscles: a muscle that was missed or under-treated keeps creasing the skin;
  • the injection technique: depth, distribution of the injection points;
  • an insufficient dose for the strength of the muscles involved1;
  • the formation of antibodies that neutralise the toxin, a rarer cause, detailed below1,2.

According to the labels, the product itself must be kept refrigerated, between 2 and 8 °C1,2: this is a handling requirement that falls to the medical practice.

It also helps to keep in mind what the toxin can and cannot do. It relaxes the muscles that crease the skin: it acts first on lines that form during movement. On lines already visible at rest, improvement concerns only some patients: in trials of one type A toxin, 74% of patients who had moderate to severe frown lines at rest were responders thirty days after the injection1. One label also notes that forehead lines caused by a loss of skin elasticity, for example with age or sun damage, may not respond to botulinum toxin3. Approved aesthetic indications target lines seen "at maximum frown" or during a forced movement1,4.

Antibodies: a rare cause

In some cases, the body can make antibodies that neutralise the toxin. The labels state that injections given too close together or at too high doses increase this risk, and that these antibodies can reduce the effectiveness of later treatments1,2,3. A literature review identifies the same factors: short intervals, booster injections, high doses per session5.

In aesthetic use, this risk remains low in the available data. In trials of one type A toxin, none of the 916 patients tested developed neutralising antibodies1. For another, no patient tested positive after repeated treatments over more than a year2. For the short-acting toxin, no neutralising antibodies were found in the 2,104 patients tested, but the label states that data are still limited4.

The same review stresses that there is no consistent link between antibodies measured in the laboratory and the clinical response5: a lack of effect is therefore not enough to conclude that you are "resistant".

An effect that fades sooner than expected

Sometimes the effect did appear but wears off earlier than expected. Here again, it all depends on the product. For type A toxins approved for aesthetic use, the effect has been shown for up to about 4 months1,2,3. For the short-acting toxin, a duration of 2 to 3 weeks matches what the label describes4: it is not a failure. If the effect decreases after repeated injections of a type A toxin, the labels ask doctors to consider other treatment methods2,3.

What to do if the toxin does not work

  1. Wait for the peak effect of the product used before judging: about a month for a type A toxin1, a week for the short-acting toxin4.
  2. Get back in touch with the doctor who performed the injection, with photos taken before the injection and at the time you judge the result, at rest and in movement.
  3. Do not ask for another early injection elsewhere. Type A labels require at least 3 months between two treatments1,3. For the short-acting toxin, repeat injections less than 6 weeks apart have not been evaluated4. A second session, with an adjusted dose, may be considered by the doctor after the failure has been analysed1.

If, on the contrary, you are worried about an effect that seems too strong or in the wrong place, see our pages on the feeling of having had too much botulinum toxin and on the side effects described in the labels.

Questions to ask your doctor

  • Which product was used, and when should its effect peak?
  • Which muscles were treated, and which were not?
  • Is the result what could be expected for my lines?
  • Should another session be considered, and when?

Key points

  • Do not judge too early: peak effect around day 30 for several type A toxins, around day 7 for the short-acting toxin2,4.
  • Treatment is considered to have failed when there is no clear improvement one month after the first session1.
  • Causes described: muscles injected, technique, insufficient dose and, more rarely, antibodies1,2.
  • No early repeat injection without your doctor’s advice1,4.

Frequently asked questions

  • How long before you can say the toxin has not worked?

    With a type A toxin, one label speaks of treatment failure when no clear improvement is seen one month after the first session1. Before then, the effect may still be building: it peaks around day 30 for some products2,3. With the short-acting toxin, the peak effect is seen around day 74; after the third week, its effect has usually already worn off4.

  • Can you become resistant to Botox?

    It is possible but rare. Injections given too close together or at too high doses can encourage the formation of antibodies that neutralise the toxin and reduce the effectiveness of later treatments1,2. In aesthetic trials, no neutralising antibodies were found in the 916 patients tested for one type A toxin1, nor in the 2,104 patients tested for the short-acting toxin4.

  • The toxin used to work, why not any more?

    Several explanations are possible: a different injection point or dose, lines that have become deeper, or, rarely, antibodies. If the effect decreases after repeated injections, one label asks doctors to consider other treatment methods2. Talk to the doctor who follows you, bringing if possible the name and date of your previous injections.

  • Should I switch products?

    It is not automatic, and the decision belongs to the doctor. A literature review mentions switching to another type of toxin among the options when effectiveness is lost because of antibodies, alongside spacing out injections5. The units of one product are not interchangeable with those of another4: a switch is therefore planned with the doctor, without simply carrying the doses over.

Sources

  1. 1.SmPC of a type A botulinum toxin approved for aesthetic use in France (BDPM, CIS 68150775) (opens in a new tab) — French public medicines database (BDPM)
  2. 2.SmPC of a type A botulinum toxin approved for aesthetic use in France (BDPM, CIS 66865211) (opens in a new tab) — French public medicines database (BDPM)
  3. 3.SmPC of a type A botulinum toxin approved for aesthetic use in France (BDPM, CIS 61592762) (opens in a new tab) — French public medicines database (BDPM)
  4. 4.Summary of product characteristics of the serotype E botulinum toxin approved in the European Union (EPAR annex I) (opens in a new tab) — European Commission (Union Register of medicinal products)
  5. 5.Bellows S., Jankovic J., immunogenicity of botulinum toxins, Toxins, 2019 (opens in a new tab) — Toxins (MDPI)
  6. 6.European public assessment report (EPAR) of the serotype E botulinum toxin (opens in a new tab) — European Commission (Union Register of medicinal products)
  7. 7.Canadian product monograph of the serotype E botulinum toxin (authorization date: 2026-06-22) (opens in a new tab) — Health Canada
Book an appointmentSOS after an injection